RESULTS
One hundred and eighteen patients (mean age:73±12years;55,7%male) treated with acenocoumarol therapy and monitored for dose adjustment were recruited. The frequency of different genotypes according to stable anticoagulation status is shown in Table 1 . Table 2 shows the frequency of genotypes in stable anticoagulated patients classified by stable anticoagulation dose (High:>28mg/week;Intermediate:7-28mg/week; Low dose:<7mg/week). The stable anticoagulation status was not associated to any gene polymorphism, and the stable anticoagulation dose was only associated to CYP2C9*3 (0,047). 
CONCLUSIONS
The achievement of a stable anticoagulation status is not associated to VKORC1, CYP2C9*2, CYP4F2*2, CYP2C19*17 or MDR1-C3435T gene polymorphisms, although the stable anticoagulation dose is associated to CYP2C9*3.
